Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274825 | 0.88 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL8466610 | 0.84 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1 | |
| SCHEMBL8465304 | 0.84 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1 | |
| SCHEMBL8156872 | 0.84 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1 | |
| SCHEMBL8143919 | 0.84 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1 | |
| SCHEMBL8465385 | 0.84 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1 | |
| SCHEMBL8465085 | 0.84 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1 | |
| SCHEMBL8467806 | 0.83 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1 | |
| SCHEMBL29870095 | 0.83 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1 | |
| SCHEMBL8465070 | 0.81 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179417-A1 | COMBINATION CHEMOTHERAPIES | SYSTEMS ONCOLOGY, LLC (US) | 2020-06-11 | — | — | US | claimed |
| US-20200179417-A1 | COMBINATION CHEMOTHERAPIES | SYSTEMS ONCOLOGY, LLC (US) | 2020-06-11 | — | — | US | disclosed |
| US-5981544-A | Mono-- or diketone tetracyclic derivatives and therapeutical uses thereof | LABORATOIRE INNOTHERA (FR) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179417-A1 | COMBINATION CHEMOTHERAPIES | ROS1, HRAS, TP53 | HSP90AA1 858/4885HSP90AB1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.